Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison Turner

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Journal of Molecular Biology|June 13, 2018
Corrigendum to "The Discovery, Engineering and Characterisation of a Highly Potent Anti-Human IL-13 Fab Fragment Designed for Administration by Inhalation" [J. Mol. Biol. 425 (2013), 577-593]Daniel Lightwood, Victoria O'Dowd, Bruce Carrington, et al.
British Journal of Haematology|January 22, 2022
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell responseKarthik Ramasamy, Ross Sadler, Sally Jeans, et al.
Research Involvement and Engagement|February 2, 2021
The practice of active patient involvement in rare disease research using ICT: experiences and lessons from the RUDY JAPAN projectNao Hamakawa, Atsushi Kogetsu, Moeko Isono, et al.
Research Involvement and Engagement|June 19, 2026
The way we do things matters: the deep integration of lived experience in the a/part of the crowd project to respond to loneliness in young adultsCandice Peart, Matthew Lewis, Jennifer Bibb, et al.
The Biochemical Journal|September 2, 2020
Monoclonal antibody stability can be usefully monitored using the excitation-energy-dependent fluorescence edge-shiftMichael J Knight, Rachel E Woolley, Anthony Kwok, et al.
Mabs|August 18, 2016
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin bindingEmma Davé, Ralph Adams, Oliver Zaccheo, et al.
European Journal of Haematology|December 20, 2023
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccinationClement Twumasi, Sally Moore, Ross Sadler, et al.
Haematologica|January 25, 2024
Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myelomaGaurav Agarwal, Sally Moore, Ross Sadler, et al.
Mabs|August 22, 2018
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentrationBryan Smith, Andrea Kiessling, Rocio Lledo-Garcia, et al.
Investigational New Drugs|May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerKhobe Chandran, Christina Guo, Simon Pacey, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of Molecular Biology|June 13, 2018
Corrigendum to "The Discovery, Engineering and Characterisation of a Highly Potent Anti-Human IL-13 Fab Fragment Designed for Administration by Inhalation" [J. Mol. Biol. 425 (2013), 577-593]Daniel Lightwood, Victoria O'Dowd, Bruce Carrington, et al.
British Journal of Haematology|January 22, 2022
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell responseKarthik Ramasamy, Ross Sadler, Sally Jeans, et al.
Research Involvement and Engagement|February 2, 2021
The practice of active patient involvement in rare disease research using ICT: experiences and lessons from the RUDY JAPAN projectNao Hamakawa, Atsushi Kogetsu, Moeko Isono, et al.
Research Involvement and Engagement|June 19, 2026
The way we do things matters: the deep integration of lived experience in the a/part of the crowd project to respond to loneliness in young adultsCandice Peart, Matthew Lewis, Jennifer Bibb, et al.
The Biochemical Journal|September 2, 2020
Monoclonal antibody stability can be usefully monitored using the excitation-energy-dependent fluorescence edge-shiftMichael J Knight, Rachel E Woolley, Anthony Kwok, et al.
Mabs|August 18, 2016
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin bindingEmma Davé, Ralph Adams, Oliver Zaccheo, et al.
European Journal of Haematology|December 20, 2023
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccinationClement Twumasi, Sally Moore, Ross Sadler, et al.
Haematologica|January 25, 2024
Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myelomaGaurav Agarwal, Sally Moore, Ross Sadler, et al.
Mabs|August 22, 2018
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentrationBryan Smith, Andrea Kiessling, Rocio Lledo-Garcia, et al.
Investigational New Drugs|May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerKhobe Chandran, Christina Guo, Simon Pacey, et al.
Pageof 5